Antitrust Antitrust

Comment: Teva probe opens new EU antitrust front on long-held grievances

By Lewis Crofts
  • 05 Mar 2021 04:51
  • 05 Mar 2021 04:51
Teva's new EU antitrust probe into its blockbuster multiple sclerosis drug breaks fresh legal ground for the European Commission, seeing it take on patent filing tactics and a suspected campaign to disparage rival drugs.

While national watchdogs have looked into similar conduct before, it’s a first for the EU enforcer and, if

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News